Financhill
Back

Entrada Therapeutics Quote, Financials, Valuation and Earnings

Invest in This AI Tech Innovator Doubling Revenue

Invest Now!
Buy
55

TRDA
Entrada Therapeutics

Last Price:
17.00
Seasonality Move:
6.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Invest in the Next Big AI Disruptor Today

Learn More

Entrada Therapeutics Price Quote

$17.00
+0.56 (+3.41%)
(Updated: October 4, 2024 at 10:25 AM ET)

Entrada Therapeutics Key Stats

Buy
55
Entrada Therapeutics (TRDA) is a Buy

Day range:
$15.98 - $16.71
52-week range:
$10.75 - $18.17
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.31
P/B ratio:
1.39%

Volume:
142.8K
Avg. volume:
146.1K
1-year change:
7.52%
Market cap:
$595.6M
Revenue:
$129M
EPS:
$2.96

How Much Does Entrada Therapeutics Make?

Is Entrada Therapeutics Growing As A Company?

  • What Is Entrada Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 4.21%
  • What Is Entrada Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Entrada Therapeutics Stock Price Performance

What Is Entrada Therapeutics 52-Week High & Low?

Entrada Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Entrada Therapeutics?

Is Entrada Therapeutics Cash Flow Positive?

  • What Is TRDA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$14.2M
  • What Is Entrada Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $102.6M
  • What Is Entrada Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $17.1M

Entrada Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    TRDA return on invested capital is 37.43%
  • What Is Entrada Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 20.55%
  • What Is TRDA Return On Equity?
    ROE is a measure of profitability and is 37.43%

Entrada Therapeutics Earnings Date & Stock Price

Entrada Therapeutics Competitors

Entrada Therapeutics Dividend Yield

Entrada Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 369.7%
Revenue: 421.16% 159.91%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 23.90
Upside from Last Price: 45.4%

Major Shareholders

  • How many TRDA shares are owned by institutional investors?
    43.7M TRDA shares are owned by institutional investors
  • How many TRDA shares are owned by insiders?
    884.2K TRDA shares are owned by insiders